Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bluestar-Endometrial01
2024-518777-34-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Feb 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 27
01
Overview
Phase 3, randomised, open-label trial of puxitatug samrotecan in endometrial cancer (EC) and carcinosarcoma (2 arms), sponsored by AstraZeneca. Primary endpoints: Progression-free survival and Overall survival. Planned start Feb 2026; status: authorised.
02
Drugs
puxitatug samrotecan
03
Conditions
endometrial cancer (EC)carcinosarcoma
Beyond the preview
Go deeper on 2024-518777-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518777-34-00.